stockrowPrestige Consumer Healthcare Inc.
PBH Healthcare Drug Manufacturers Specialty & Generic
Prestige Consumer Healthcare Inc.’s revenue for fiscal 2026 (year ended March 2026) was $1.1 billion, down 4.31% from fiscal 2025.
- Revenue
- +22.7%
- EPS
- −38.4%
- Free cash flow
- −38.2%
- Total debt
- +100.9%
Quarter to September 2026, against a year earlier
Follow PBH
Alert me
Prestige Consumer Healthcare Inc. (PBH) Return on equity
Prestige Consumer Healthcare Inc.'s return on equity over the twelve months to 30 September 2026 was 8.23%, down 2.0 percentage points from fiscal 2026 (10.2%). Over the past ten years it has ranged from −5.44% (fiscal 2023) to 33.9% (fiscal 2018); the current reading is higher than 33% of that period. That is above the Drug Manufacturers Specialty & Generic industry median of −0.80% and above the Healthcare sector median of −26.3%.
Return on equity, annual
Embed this chart
Annual newest first
| Period | Return on equity | Change (points) |
|---|---|---|
| FY2026 | 10.2% | (2.08) |
| FY2025 | 12.3% | (1.20) |
| FY2024 | 13.5% | 18.94 |
| FY2023 | −5.44% | (19.43) |
| FY2022 | 14.0% | 0.97 |
| FY2021 | 13.0% | 0.47 |
| FY2020 | 12.6% | 15.70 |
| FY2019 | −3.15% | (37.09) |
| FY2018 | 33.9% | 25.08 |
| FY2017 | 8.86% | (5.70) |
Against its own ten years
Return on equity against peers
| Company | Return on equity |
|---|---|
| BCRX BioCryst Pharmaceuticals, Inc. compare | 91.6% |
| PBH Prestige Consumer Healthcare Inc. | 8.23% |
| HCM HUTCHMED (China) Limited Sponsored ADR compare | 0.00% |
| RGC Regencell Bioscience Holdings Limited compare | 0.00% |
| ALVO Alvotech compare | 0.00% |
| XERS Xeris Biopharma Holdings, Inc. compare | −27.1% |
| TRLV Trulieve Cannabis Corp. compare | −45.5% |
| PRGO Perrigo Company plc compare | −51.4% |
| AMLX Amylyx Pharmaceuticals, Inc. compare | −74.7% |
| Drug Manufacturers Specialty & Generic industry median | −0.80% |
| Healthcare sector median | −26.3% |
| Market median | 0.51% |
What Return on equity is
ROE shows how much profit a company earns for its shareholders on the equity they have in the business.
Annual: Net Income Allotted to Shareholders ÷ Average Common Equity; TTM: Net Income Allotted to Shareholders ÷ Average Common Equity (latest quarter)
More on PBH
- Revenue
- Net income
- EPS (diluted)
- EBITDA
- Free cash flow
- Operating cash flow
- Gross margin
- Operating margin
- Net margin
- Free cash flow margin
- P/E ratio
- P/S ratio
- P/B ratio
- Price to free cash flow
- EV/EBITDA
- EV/Sales
- EV/FCF
- Return on assets
- Return on invested capital
- Debt to equity
- Current ratio
- Total debt
- Shares outstanding
- Book value per share
- Revenue growth
- Piotroski F-score
- Altman Z-score
- Beneish M-score
- The full statement